EFM
E Fund Management Portfolio holdings
AUM
$2.1B
1-Year Return
23.31%
This Quarter Return
+1.57%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$1.61B
AUM Growth
+$36.4M
(+2.3%)
Cap. Flow
+$105M
Cap. Flow
% of AUM
6.47%
Top 10 Holdings %
Top 10 Hldgs %
61.46%
Holding
387
New
81
Increased
131
Reduced
147
Closed
19
Top Buys
| 1 |
ASE Group
ASX
|
$25.3M |
| 2 |
Microsoft
MSFT
|
$12.9M |
| 3 |
NVIDIA
NVDA
|
$11.9M |
| 4 |
Apple
AAPL
|
$9.18M |
| 5 |
Amazon
AMZN
|
$7.47M |
Top Sells
| 1 |
Sea Limited
SE
|
$24.3M |
| 2 |
Advanced Micro Devices
AMD
|
$16.8M |
| 3 |
TSMC
TSM
|
$8M |
| 4 |
Weibo
WB
|
$2.43M |
| 5 |
Pinduoduo
PDD
|
$2.4M |
Sector Composition
| 1 | Consumer Discretionary | 40.2% |
| 2 | Technology | 29.79% |
| 3 | Communication Services | 9.9% |
| 4 | Healthcare | 5.71% |
| 5 | Real Estate | 4.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
176
American Electric Power
AEP
$58.1B
| $446K | 0.03% |
5,181
-45
| -0.9% | -$3.87K |
|
|
BPMC
177
DELISTED
Blueprint Medicines
BPMC
| $445K | 0.03% |
4,695
-1,798
| -28% | -$171K |
|
178
Natera
NTRA
$22.9B
| $445K | 0.03% |
4,866
-3,394
| -41% | -$310K |
|
|
CERE
179
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $444K | 0.03% |
10,506
+2,907
| +38% | +$123K |
|
180
Immunovant
IMVT
$2.81B
| $442K | 0.03% |
13,675
+1,419
| +12% | +$45.8K |
|
181
Carnival Corp
CCL
$43.1B
| $442K | 0.03% |
27,038
| – | – |
|
182
BioMarin Pharmaceuticals
BMRN
$10.9B
| $440K | 0.03% |
5,042
-126
| -2% | -$11K |
|
|
ALPN
183
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $439K | 0.03% |
+11,087
| New | +$439K |
|
184
Fastenal
FAST
$57.7B
| $434K | 0.03% |
11,264
-116
| -1% | -$4.47K |
|
185
DoorDash
DASH
$106B
| $434K | 0.03% |
3,152
-39
| -1% | -$5.37K |
|
186
Revolution Medicines
RVMD
$7.28B
| $433K | 0.03% |
13,438
-6,094
| -31% | -$196K |
|
187
Vertiv
VRT
$48B
| $430K | 0.03% |
+5,267
| New | +$430K |
|
188
Neurocrine Biosciences
NBIX
$13.9B
| $429K | 0.03% |
3,113
-983
| -24% | -$136K |
|
189
Paychex
PAYX
$49.4B
| $429K | 0.03% |
3,495
-53
| -1% | -$6.51K |
|
190
Roivant Sciences
ROIV
$8.58B
| $428K | 0.03% |
40,576
-8,284
| -17% | -$87.3K |
|
191
Ionis Pharmaceuticals
IONS
$9.46B
| $426K | 0.03% |
9,825
-40
| -0.4% | -$1.73K |
|
192
Altimmune
ALT
$313M
| $425K | 0.03% |
+41,709
| New | +$425K |
|
193
Vericel Corp
VCEL
$1.7B
| $424K | 0.03% |
8,145
+2,462
| +43% | +$128K |
|
194
Insmed
INSM
$30.1B
| $423K | 0.03% |
15,577
-1,601
| -9% | -$43.4K |
|
195
Halozyme
HALO
$8.58B
| $422K | 0.03% |
10,385
-1,638
| -14% | -$66.6K |
|
196
Denali Therapeutics
DNLI
$2.16B
| $422K | 0.03% |
20,552
+3,262
| +19% | +$66.9K |
|
197
Alnylam Pharmaceuticals
ALNY
$59.5B
| $421K | 0.03% |
2,814
-526
| -16% | -$78.6K |
|
198
Syndax Pharmaceuticals
SNDX
$1.39B
| $420K | 0.03% |
17,638
-3,942
| -18% | -$93.8K |
|
199
Kraft Heinz
KHC
$31.9B
| $419K | 0.03% |
11,353
-280
| -2% | -$10.3K |
|
200
Ironwood Pharmaceuticals
IRWD
$179M
| $419K | 0.03% |
48,097
+10,410
| +28% | +$90.7K |
|